

VPA10826/002/001

**Dexatat 2 mg/ml solution for Injection**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - B45	VNRA - Vet - B45 - Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile active substance, starting material, reagent or intermediate, excipient - B45 Changes to the quality part of the dossier: Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	13/11/24
Vet - B44	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	16/08/22
Vet - B44	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	16/08/22
B.II.b.4.a	IB - B.II.b.4.a - a) Up to 10-fold compared to the originally approved batch size - B.II.b.4.a - QUALITY CHANGES - FINISHED PRODUCT - Manufacture - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	16/02/22